Abionic announces successful completion of sepsis trial

Abionic is engaged in an ambitious clinical program demonstrating how the Pancreatic Stone Protein (PSP) test could lead to a better recognition and clinical management of sepsis. The study was designed to establish performance characteristics of the PSP test in the early detection of sepsis. A total of 300 adult ICU (intensive Care Unit) patients at high risk of developing sepsis admitted to 14 ICU sites in the UK, France, Italy and Switzerland were enrolled. Bedside measurement of PSP on the abioSCOPE clearly shows correlation with the onset of sepsis.

During the study, the majority of patients who developed sepsis already showed high PSP concentration values 24 hours before the diagnosis with current methods. Time being critical with this condition, the outcome for patients could dramatically be improved with a gain of 24 hours. The complete clinical data is currently in preparation for peer reviewed publication at the beginning of 2020.

“We are extremely proud to announce the successful completion of our pivotal sepsis trial and thank all the people who make this possible.” said Fabien Rebeaud, PhD, Chief Scientific Officer of Abionic. “Our study demonstrates that, from a drop of blood and in 5 minutes sepsis can be identified several dozen of hours upfront than today’s standard of care. This opens tremendous perspectives for the improvement of the diagnosis of sepsis and its timely, optimal clinical management, for the benefit of the patient.”

Abionic is about to launch a multi-center clinical trial in the U.S to further establish the clinical value and fulfill FDA registration requirements. The first patient in is expected in October 2019. The company’s vision is to have an abioSCOPE in every single Intensive Care Unit (ICU) and Emergency Room (ER) to bring the right diagnosis immediately to patients.